MedKoo Cat#: 564657 | Name: SR12460
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR12460 is an inhibitor of tumor necrosis factor α (TNF-α)- and lipopolysaccharide (LPS)-induced NF-κB activation by blocking the interaction between IKKβ and NEMO, suppressing LPS-induced acute pulmonary inflammation in mice.

Chemical Structure

SR12460
SR12460
CAS#2055101-66-9

Theoretical Analysis

MedKoo Cat#: 564657

Name: SR12460

CAS#: 2055101-66-9

Chemical Formula: C15H14ClF2N3O

Exact Mass: 325.0793

Molecular Weight: 325.74

Elemental Analysis: C, 55.31; H, 4.33; Cl, 10.88; F, 11.66; N, 12.90; O, 4.91

Price and Availability

Size Price Availability Quantity
1mg USD 300.00 2 Weeks
5mg USD 500.00 2 Weeks
10mg USD 750.00 2 Weeks
25mg USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SR-12460; SR 12460; SR12460
IUPAC/Chemical Name
2-((5-Chloropyridin-2-yl)amino)-N-(3,5-difluorophenethyl)acetamide
InChi Key
XNEWRBBKUMGNPC-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H14ClF2N3O/c16-11-1-2-14(20-8-11)21-9-15(22)19-4-3-10-5-12(17)7-13(18)6-10/h1-2,5-8H,3-4,9H2,(H,19,22)(H,20,21)
SMILES Code
O=C(NCCC1=CC(F)=CC(F)=C1)CNC2=NC=C(Cl)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Biological target:
SR12460 is a mimetic of the IκB kinase β (IKKβ) NEMO/IKKγ-binding domain (NBD) that inhibits the protein-protein interaction between the IKK complex subunits NF-κB essential modulator (NEMO/IKKγ) and IKKβ.
In vitro activity:
To be determined
In vivo activity:
NF-κB essential modulator (NEMO)-binding domain (NBD) mimetics have potential in inflammatory and degenerative disease treatments. SR12343 and SR12460 inhibited TNF-α- and LPS-induced NF-κB activation by blocking the interaction between IKKβ and NEMO and suppressed LPS-induced acute pulmonary inflammation in mice. In a mouse model of Duchenne muscular dystrophy, chronic treatment with SR12343 and SR12460 attenuated inflammatory infiltration, necrosis and muscle degeneration. Reference: PLoS Biol. 2018 Jun 11;16(6):e2004663. https://pubmed.ncbi.nlm.nih.gov/29889904/
Solvent mg/mL mM comments
Solubility
DMF 30.0 92.10
DMSO 15.0 46.05
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 325.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhao J, Zhang L, Mu X, Doebelin C, Nguyen W, Wallace C, Reay DP, McGowan SJ, Corbo L, Clemens PR, Wilson GM, Watkins SC, Solt LA, Cameron MD, Huard J, Niedernhofer LJ, Kamenecka TM, Robbins PD. Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation. PLoS Biol. 2018 Jun 11;16(6):e2004663. doi: 10.1371/journal.pbio.2004663. PMID: 29889904; PMCID: PMC6013238.
In vitro protocol:
To be determined
In vivo protocol:
1. Zhao J, Zhang L, Mu X, Doebelin C, Nguyen W, Wallace C, Reay DP, McGowan SJ, Corbo L, Clemens PR, Wilson GM, Watkins SC, Solt LA, Cameron MD, Huard J, Niedernhofer LJ, Kamenecka TM, Robbins PD. Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation. PLoS Biol. 2018 Jun 11;16(6):e2004663. doi: 10.1371/journal.pbio.2004663. PMID: 29889904; PMCID: PMC6013238.
1: Zhao J, Zhang L, Mu X, Doebelin C, Nguyen W, Wallace C, Reay DP, McGowan SJ, Corbo L, Clemens PR, Wilson GM, Watkins SC, Solt LA, Cameron MD, Huard J, Niedernhofer LJ, Kamenecka TM, Robbins PD. Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation. PLoS Biol. 2018 Jun 11;16(6):e2004663. doi: 10.1371/journal.pbio.2004663. eCollection 2018 Jun. PubMed PMID: 29889904; PubMed Central PMCID: PMC6013238.